新藥顯示出治療血癌的潛力
New drug shows promise for treating blood cancer
Updated at: June 12, 2026 at 01:30 AM
截至2026年6月，在EHA與ASCO大會上發表的醫學突破正改變著血液癌症的治療。
As of June 2026, medical breakthroughs presented at the EHA and ASCO congresses are transforming blood cancer care.
近期的臨床試驗突顯了兩大進展方向：提升臨床療效與更便利的治療傳輸。
Recent clinical trials highlight two major areas of progress: improved clinical efficacy and more practical treatment delivery.
在存活率方面，新的藥物組合展現了極大的潛力。
In terms of survival, new drug combinations are showing great potential.
SENTRY試驗顯示，合併使用Selinexor與Ruxolitinib為骨髓纖維化患者提供了一條有前景的途徑，而POLARGO試驗則證實，將polatuzumab vedotin加入R-GemOx中，能顯著幫助復發性淋巴瘤患者。
The SENTRY trial revealed that combining Selinexor and Ruxolitinib offers a promising path for patients with myelofibrosis, while the POLARGO trial proved that adding polatuzumab vedotin to R-GemOx significantly helps patients with relapsed lymphoma.
除了新藥，專家們正致力於使治療更易取得。
Beyond new drugs, experts are focusing on making treatments more accessible.
一項關鍵的發展是轉向門診護理以進行先進的免疫療法。
A key development is the shift toward outpatient care for advanced immunotherapies.
例如，EPCORE NHL-6試驗確認epcoritamab可以在醫院外安全給藥，使社區腫瘤科醫師能在不需長時間住院的情況下治療患者。
For instance, the EPCORE NHL-6 trial confirmed that epcoritamab can be safely administered outside of a hospital, allowing community oncologists to treat patients without requiring long hospital stays.
此外，研究人員正推動免化療的選項，例如固定療程的venetoclax組合，以降低治療毒性。
Furthermore, researchers are pushing for chemotherapy-free options, such as fixed-duration venetoclax combinations, to reduce treatment toxicity.
這些進展反映了腫瘤學的重大轉變，優先考量新療法的有效性以及全球患者取得治療的便利性。
These advancements reflect a significant shift in oncology, prioritizing both the effectiveness of new therapies and the ease of access for patients globally.
免責聲明：本資訊僅供教育用途；請諮詢腫瘤科醫師以獲取醫療建議。
Disclaimer: This information is for educational purposes only; consult an oncologist for medical advice.
